688739 成大生物
已收盘 04-15 15:00:01
资讯
新帖
简况
每周股票复盘：成大生物（688739）累计回购38.49万股
证券之星 · 04-05
每周股票复盘：成大生物（688739）累计回购38.49万股
成大生物（688739）披露以集中竞价交易方式回购公司股份的进展公告，4月2日股价下跌0.24%
证券之星 · 04-02
成大生物（688739）披露以集中竞价交易方式回购公司股份的进展公告，4月2日股价下跌0.24%
每周股票复盘：成大生物（688739）独立董事任期届满申请离任
证券之星 · 03-22
每周股票复盘：成大生物（688739）独立董事任期届满申请离任
成大生物（688739）披露独立董事任期届满离任公告，3月17日股价上涨0.08%
证券之星 · 03-17
成大生物（688739）披露独立董事任期届满离任公告，3月17日股价上涨0.08%
每周股票复盘：成大生物（688739）子公司通过GMP检查提升竞争力
证券之星 · 03-15
每周股票复盘：成大生物（688739）子公司通过GMP检查提升竞争力
成大生物（688739）披露全资子公司通过药品GMP符合性检查公告，3月9日股价上涨0.16%
证券之星 · 03-09
成大生物（688739）披露全资子公司通过药品GMP符合性检查公告，3月9日股价上涨0.16%
成大生物(688739.SH)：本溪子公司通过药品GMP符合性检查
智通财经 · 03-09
成大生物(688739.SH)：本溪子公司通过药品GMP符合性检查
每周股票复盘：成大生物（688739）回购进展披露
证券之星 · 03-08
每周股票复盘：成大生物（688739）回购进展披露
成大生物（688739）披露回购股份进展公告，3月2日股价下跌1.5%
证券之星 · 03-02
成大生物（688739）披露回购股份进展公告，3月2日股价下跌1.5%
成大生物：2026年2月公司未实施股份回购
证券日报 · 03-02
成大生物：2026年2月公司未实施股份回购
每周股票复盘：成大生物（688739）获人二倍体狂犬疫苗注册证
证券之星 · 03-01
每周股票复盘：成大生物（688739）获人二倍体狂犬疫苗注册证
成大生物（688739）披露2025年度业绩快报公告，2月27日股价下跌0.04%
证券之星 · 02-27
成大生物（688739）披露2025年度业绩快报公告，2月27日股价下跌0.04%
成大生物（688739）披露2026年第一次临时股东会决议公告，2月24日股价上涨1.05%
证券之星 · 02-24
成大生物（688739）披露2026年第一次临时股东会决议公告，2月24日股价上涨1.05%
成大生物(688739.SH)：人用二倍体狂犬疫苗获药品注册证书
智通财经 · 02-24
成大生物(688739.SH)：人用二倍体狂犬疫苗获药品注册证书
成大生物最新公告：选举徐飚为公司第五届董事会联席董事长
证券之星 · 02-12
成大生物最新公告：选举徐飚为公司第五届董事会联席董事长
每周股票复盘：成大生物（688739）拟出资4亿元参设医药产业基金
证券之星 · 02-08
每周股票复盘：成大生物（688739）拟出资4亿元参设医药产业基金
成大生物（688739）披露拟参与设立5.02亿元生物医药产业投资基金，2月5日股价上涨0.39%
证券之星 · 02-05
成大生物（688739）披露拟参与设立5.02亿元生物医药产业投资基金，2月5日股价上涨0.39%
成大生物拟与控股股东及其关联方共同设立规模最高10亿元产业投资基金
美股速递 · 02-05
成大生物拟与控股股东及其关联方共同设立规模最高10亿元产业投资基金
成大生物（688739）披露以集中竞价交易方式回购公司股份的进展公告，2月2日股价下跌2.26%
证券之星 · 02-02
成大生物（688739）披露以集中竞价交易方式回购公司股份的进展公告，2月2日股价下跌2.26%
每周股票复盘：成大生物（688739）2025年净利预降59%
证券之星 · 02-01
每周股票复盘：成大生物（688739）2025年净利预降59%
加载更多
公司概况
公司名称：
辽宁成大生物股份有限公司
所属行业：
医药制造业
上市日期：
2021-10-28
主营业务：
辽宁成大生物股份有限公司的主营业务是人用疫苗的研发、生产与销售。公司的主要产品是人用狂犬病疫苗和人用乙脑灭活疫苗。
发行价格：
110.00
{"stockData":{"symbol":"688739","market":"SH","secType":"STK","nameCN":"成大生物","latestPrice":24.82,"timestamp":1776236401000,"preClose":24.55,"halted":0,"volume":1810164,"delay":0,"changeRate":0.011,"floatShares":416000000,"shares":416000000,"eps":0.4273,"marketStatus":"已收盘","change":0.27,"latestTime":"04-15 15:00:01","open":24.8,"high":24.91,"low":24.63,"amount":44853900,"amplitude":0.0114,"askPrice":24.84,"askSize":41,"bidPrice":24.82,"bidSize":45,"shortable":0,"etf":0,"ttmEps":0.4273,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776303000000},"marketStatusCode":5,"adr":0,"adjPreClose":24.55,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776216600000,1776223800000],[1776229200000,1776236400000]],"highLimit":27.01,"lowLimit":22.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":416450000,"isCdr":false,"pbRate":1.1,"roa":"--","peRate":58.085654,"roe":"1.74%","epsLYR":0.83,"committee":-0.012153,"marketValue":10336000000,"turnoverRate":0.0043,"status":0,"afterMarket":{"amount":0,"volume":0,"close":24.82,"buyVolume":0,"sellVolume":0,"time":1776238437558,"indexStatus":"已收盘 04-15 15:30:00","preClose":24.55},"floatMarketCap":10336000000},"requestUrl":"/m/hq/s/688739","defaultTab":"news","newsList":[{"id":"2625619947","title":"每周股票复盘：成大生物（688739）累计回购38.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619947?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:12","pubTimestamp":1775329932,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，成大生物报收于24.41元，较上周的24.39元上涨0.08%。本周，成大生物4月2日盘中最高价报25.12元。成大生物当前最新总市值101.66亿元，在生物制品板块市值排名27/51，在两市A股市值排名1878/5193。截至2026年3月31日，累计回购股份384,899股，占公司总股本0.092%，已支付资金总额10,789,216.56元，回购最高价为29.61元/股，最低价为27.20元/股。2026年3月未实施回购。上述回购进展符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624500667","title":"成大生物（688739）披露以集中竞价交易方式回购公司股份的进展公告，4月2日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624500667","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624500667?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:51","pubTimestamp":1775141473,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘，成大生物报收于24.91元，较前一交易日下跌0.24%，最新总市值为103.74亿元。该股当日开盘25.01元，最高25.12元，最低24.83元，成交额达4486.03万元，换手率为0.43%。公司于2026年4月2日披露《关于以集中竞价交易方式回购公司股份的进展公告》。截至2026年3月31日，累计回购股份384,899股，占公司总股本0.092%，已支付资金总额10,789,216.56元，回购最高价为29.61元/股，最低价为27.20元/股。2026年3月未实施回购。上述回购进展符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200042888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621918977","title":"每周股票复盘：成大生物（688739）独立董事任期届满申请离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2621918977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621918977?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:27","pubTimestamp":1774121229,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，成大生物报收于24.78元，较上周的25.68元下跌3.5%。本周关注点公司公告汇总：三位独立董事因任期届满申请离任，辞职将在股东大会选举新任后生效。公司公告汇总辽宁成大生物股份有限公司董事会近日收到独立董事陈克兢先生、刘晓辉先生、张克坚先生提交的书面辞职报告。截至公告日，陈克兢、张克坚未持有公司股份，刘晓辉持有公司股份20,000股。在新任独立董事就任前，三人将继续履行职责。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620475281","title":"成大生物（688739）披露独立董事任期届满离任公告，3月17日股价上涨0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620475281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620475281?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:58","pubTimestamp":1773759492,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，成大生物报收于25.36元，较前一交易日上涨0.08%，最新总市值为105.61亿元。近日，辽宁成大生物股份有限公司发布《关于公司独立董事任期届满离任的公告》。公告显示，公司董事会收到独立董事陈克兢先生、刘晓辉先生、张克坚先生提交的书面辞职报告。截至公告日，陈克兢、张克坚未持有公司股份，刘晓辉持有公司股份20,000股。在新任独立董事就任前，三人将继续履行职责。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700042436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619120200","title":"每周股票复盘：成大生物（688739）子公司通过GMP检查提升竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2619120200","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619120200?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:24","pubTimestamp":1773512652,"startTime":"0","endTime":"0","summary":"本周关注点来自公司公告汇总：全资子公司生产基地通过药品GMP符合性检查，具备疫苗商业化生产条件。公司公告汇总辽宁成大生物股份有限公司全资子公司成大生物（本溪）有限公司收到辽宁省药品监督管理局签发的《药品GMP符合性现场检查结果通知书》，其生产基地生产的冻干人用狂犬病疫苗通过药品GMP符合性检查。本次通过检查标志着本溪子公司具备该疫苗的商业化生产条件，有利于提升公司质量管控能力和市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618518627","title":"成大生物（688739）披露全资子公司通过药品GMP符合性检查公告，3月9日股价上涨0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618518627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618518627?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:50","pubTimestamp":1773067830,"startTime":"0","endTime":"0","summary":"近日，辽宁成大生物股份有限公司发布《关于全资子公司通过药品GMP符合性检查的公告》。公告显示，公司全资子公司成大生物（本溪）有限公司收到辽宁省药品监督管理局签发的《药品GMP符合性现场检查结果通知书》，其生产基地生产的冻干人用狂犬病疫苗通过药品GMP符合性检查。本次通过检查标志着本溪子公司具备该疫苗的商业化生产条件，有利于提升公司质量管控能力和市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900035629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618645642","title":"成大生物(688739.SH)：本溪子公司通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2618645642","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618645642?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:07","pubTimestamp":1773043644,"startTime":"0","endTime":"0","summary":"智通财经APP讯，成大生物 发布公告，公司全资子公司成大生物(本溪)有限公司近日收到辽宁省药品监督管理局签发的《药品GMP符合性现场检查结果通知书》。本溪子公司生产基地生产的冻干人用狂犬病疫苗已通过药品生产质量管理规范符合性检查。本溪子公司本次通过药品GMP符合性检查，标志着其生产基地已具备冻干人用狂犬病疫苗商业化生产条件，生产质量管理体系符合药品监管相关规范要求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"成大生物(688739.SH)：本溪子公司通过药品GMP符合性检查","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617638036","title":"每周股票复盘：成大生物（688739）回购进展披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2617638036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617638036?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:55","pubTimestamp":1772909711,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，成大生物报收于25.26元，较上周的25.96元下跌2.7%。本周，成大生物3月2日盘中最高价报25.88元。成大生物当前最新总市值105.2亿元，在生物制品板块市值排名28/51，在两市A股市值排名1974/5190。本周关注点公司公告汇总：截至2026年2月28日，成大生物累计回购股份384,899股，支付资金总额10,789,216.56元。2026年2月公司未实施回购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616135625","title":"成大生物（688739）披露回购股份进展公告，3月2日股价下跌1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616135625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616135625?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:14","pubTimestamp":1772464459,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，成大生物报收于25.57元，较前一交易日下跌1.5%，最新总市值为106.49亿元。该股当日开盘25.88元，最高25.88元，最低25.45元，成交额达6387.65万元，换手率为0.6%。近日，辽宁成大生物股份有限公司发布《关于以集中竞价交易方式回购公司股份的进展公告》。2026年2月公司未实施回购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616935815","title":"成大生物：2026年2月公司未实施股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2616935815","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616935815?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:38","pubTimestamp":1772458680,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月2日，成大生物发布公告称，2026年2月，公司未实施股份回购。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-02/doc-inhprfsf1235398.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-02/doc-inhprfsf1235398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616454738","title":"每周股票复盘：成大生物（688739）获人二倍体狂犬疫苗注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616454738","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616454738?lang=zh_cn&edition=full","pubTime":"2026-03-01 03:02","pubTimestamp":1772305334,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：冻干人用狂犬病疫苗获药品注册证书，系国内首个覆盖三种免疫程序的产品。公司公告汇总辽宁成大生物股份有限公司全资子公司成大生物（本溪）有限公司近日收到国家药品监督管理局签发的冻干人用狂犬病疫苗《药品注册证书》，批准文号为国药准字S20260012，有效期至2031年2月9日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614936850","title":"成大生物（688739）披露2025年度业绩快报公告，2月27日股价下跌0.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614936850","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614936850?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:30","pubTimestamp":1772206229,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，成大生物报收于25.96元，较前一交易日下跌0.04%，最新总市值为108.11亿元。该股当日开盘25.9元，最高26.0元，最低25.89元，成交额达2949.33万元，换手率为0.27%。近日，辽宁成大生物股份有限公司发布2025年度业绩快报，营业总收入139,028.74万元，同比下降17.06%；归属于母公司所有者的净利润13,761.67万元，同比下降59.86%；扣除非经常性损益的净利润同比下降85.79%。报告期末总资产975,181.82万元，较期初下降2.98%。上述数据为初步核算，未经审计，最终以年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613687797","title":"成大生物（688739）披露2026年第一次临时股东会决议公告，2月24日股价上涨1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613687797","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613687797?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:33","pubTimestamp":1771929198,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，成大生物报收于25.9元，较前一交易日上涨1.05%，最新总市值为107.86亿元。近日，辽宁成大生物股份有限公司发布《2026年第一次临时股东会决议公告》。公告显示，公司于2026年2月12日召开2026年第一次临时股东会，会议由董事会召集，董事长李宁主持，采用现场与网络投票结合方式召开。其中，关联交易议案对中小投资者单独计票，关联股东辽宁成大股份有限公司回避表决。出席会议股东所持表决权占公司总表决权的58.3244%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613776011","title":"成大生物(688739.SH)：人用二倍体狂犬疫苗获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2613776011","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613776011?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:38","pubTimestamp":1771918694,"startTime":"0","endTime":"0","summary":"智通财经APP讯，成大生物(688739.SH)公告，公司全资子公司成大生物(本溪)有限公司(简称“本溪子公司”)于近日收到国家药品监督管理局签发的冻干人用狂犬病疫苗(人二倍体细胞)(简称“人用二倍体狂犬疫苗”)《药品注册证书》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"成大生物(688739.SH)：人用二倍体狂犬疫苗获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688739","BK0239","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610097892","title":"成大生物最新公告：选举徐飚为公司第五届董事会联席董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2610097892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610097892?lang=zh_cn&edition=full","pubTime":"2026-02-12 23:39","pubTimestamp":1770910796,"startTime":"0","endTime":"0","summary":"成大生物(688739.SH)公告称，公司于2026年2月12日召开董事会，审议通过选举徐飚为公司第五届董事会联席董事长的议案。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200039557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609952529","title":"每周股票复盘：成大生物（688739）拟出资4亿元参设医药产业基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2609952529","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609952529?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:20","pubTimestamp":1770488424,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，成大生物报收于25.71元，较上周的26.15元下跌1.68%。本周关注点公司公告汇总：成大生物拟作为有限合伙人认缴出资4亿元参与设立成大生物医药产业投资基金。辽宁成大生物拟与控股股东辽宁成大及其全资子公司共同发起设立成大生物医药产业投资基金，基金设立规模为50,200万元，公司作为有限合伙人认缴出资4亿元。本次事项构成关联交易，需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609309248","title":"成大生物（688739）披露拟参与设立5.02亿元生物医药产业投资基金，2月5日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309248","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609309248?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:26","pubTimestamp":1770301580,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，成大生物报收于25.89元，较前一交易日上涨0.39%，最新总市值为107.82亿元。该股当日开盘25.8元，最高26.07元，最低25.71元，成交额达5943.37万元，换手率为0.55%。近日，辽宁成大生物股份有限公司披露《2026年第一次临时股东会会议资料》。公告显示，公司拟与控股股东辽宁成大及其全资子公司共同发起设立成大生物医药产业投资基金，基金设立规模为50,200万元，公司作为有限合伙人认缴出资4亿元。本次事项构成关联交易，需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161726","688739","BK0239","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117273287","title":"成大生物拟与控股股东及其关联方共同设立规模最高10亿元产业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=1117273287","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117273287?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:27","pubTimestamp":1770280044,"startTime":"0","endTime":"0","summary":"成大生物（688739）发布公告称，公司计划与控股股东及其关联方合作，共同设立一支总规模不超过10亿元人民币的产业投资基金。该基金将重点投向生物医药、医疗器械等与大健康产业相关的优质项目，旨在通过资本运作加速产业链布局，提升公司长期核心竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608857969","title":"成大生物（688739）披露以集中竞价交易方式回购公司股份的进展公告，2月2日股价下跌2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608857969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608857969?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:56","pubTimestamp":1770026182,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，成大生物报收于25.56元，较前一交易日下跌2.26%，最新总市值为106.44亿元。近日，辽宁成大生物股份有限公司发布《关于以集中竞价交易方式回购公司股份的进展公告》。公告显示，公司于2025年6月19日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购期限为2025年6月19日至2026年6月18日，预计回购金额为1,000万元至2,000万元，用于员工持股计划或股权激励，回购价格不超过38.00元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200026721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608270077","title":"每周股票复盘：成大生物（688739）2025年净利预降59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608270077","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608270077?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:27","pubTimestamp":1769887630,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，成大生物报收于26.15元，较上周的26.81元下跌2.46%。本周关注点来自业绩披露要点：成大生物预计2025年归母净利润同比下降59.34%至63.98%。来自公司公告汇总：公司拟终止hib疫苗研发项目，计提减值准备8,067万元。公司公告汇总辽宁成大生物股份有限公司预计2025年年度归母净利润为12,347.00万元至13,939.00万元，同比减少59.34%至63.98%；扣非净利润为3,185.00万元至4,777.00万元，同比减少85.25%至90.16%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776275127940,"stockEarnings":[{"period":"1week","weight":-0.0068},{"period":"1month","weight":-0.0205},{"period":"3month","weight":-0.0766},{"period":"6month","weight":-0.0701},{"period":"1year","weight":0.0272},{"period":"ytd","weight":-0.0365}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":-0.0141},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"辽宁成大生物股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24286人(较上一季度减少4.17%)","perCapita":"17147股","listingDate":"2021-10-28","address":"辽宁省沈阳市浑南区新放街1号","registeredCapital":"41645万元","survey":" 辽宁成大生物股份有限公司的主营业务是人用疫苗的研发、生产与销售。公司的主要产品是人用狂犬病疫苗和人用乙脑灭活疫苗。","listedPrice":110},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"成大生物(688739)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供成大生物(688739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"成大生物,688739,成大生物股票,成大生物股票老虎,成大生物股票老虎国际,成大生物行情,成大生物股票行情,成大生物股价,成大生物股市,成大生物股票价格,成大生物股票交易,成大生物股票购买,成大生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"成大生物(688739)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供成大生物(688739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}